However, it should be cautioned that due to mutational heterogeneity of STK11 and the relatively high concentrations of palbociclib used to observe the drug response in lung cancer cells, future studies will be needed to probe the molecular basis for STK11-directed therapeutic strategies. Here, STK11 is linked to lung carcinoma.